SAB BIOTHERAPEUTICS, INC. (SABS) Return on equity 2020–2025
SAB BIOTHERAPEUTICS, INC. (SABS) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
8.8%FY2025 · since FY2020: 51.6% → 8.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 8.8% | +140.1 pp |
| FY2024 | -131.3% | -57.7 pp |
| FY2023 | -73.6% | -13.3 pp |
| FY2022 | -60.3% | -15.9 pp |
| FY2021 | -44.5% | -96.0 pp |
| FY2020 | 51.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice